ReviewMultiple sclerosis (Houndmills, Basingstoke, England)2023
Enhancing diversity of clinical trial populations in multiple sclerosis.
Review in Multiple sclerosis (Houndmills, Basingstoke, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Best practice exercise for emerging depression in multiple sclerosis: A systematic review and meta-analysis.Clinical rehabilitation · 2024Pooled it
- Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single-Arm Clinical Trial.Annals of neurology · 2026Trial
- Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.Neurology · 2024Trial
- Diverse Recruitment for Clinical Trials Using Three Diversity-Enhancing Interventions: Qualitative Study.JMIR formative research · 2026Article
- Strategies employed to facilitate representativeness in hematology clinical research: a survey of ASH investigators.Blood advances · 2026Article
- Serum miRNA-155 and TREM2 as Non-Invasive Biomarkers for Monitoring Neuroinflammation and Disease Activity in Multiple Sclerosis.Molecular neurobiology · 2026Review
- Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.Neurology · 2026Article
- Article
- Vocational rehabilitation for people with multiple sclerosis: A systematic scoping review of international evidence.PloS one · 2026Article
- Epidemiology and healthcare access in Brazilian multiple sclerosis patients: insights from the BRANDO database.Arquivos de neuro-psiquiatria · 2025Article
- Review
- Advancing multiple sclerosis management in older adults.Nature reviews. Neurology · 2025Article
- Embodiment of structural racism and multiple sclerosis risk and outcomes in the USA.Nature reviews. Neurology · 2025Review
- Exploring the role of sex hormones and gender diversity in multiple sclerosis.Nature reviews. Neurology · 2025Article
- The refined Pathways to Cures Research Roadmap for multiple sclerosis cures.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Article
- Rural cancer disparities from Oklahoma cancer and vital records registries 2016-2020.Cancer epidemiology · 2024Article
- A tale of race and B cells in multiple sclerosis.Nature reviews. Neurology · 2024Article
- Participant diversity in clinical trials of rehabilitation interventions for people with multiple sclerosis: A scoping review.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Article
- Enhancing involvement of people with multiple sclerosis in clinical trial design.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Review
- Setting priorities for how future research in multiple sclerosis in Canada considers equity, diversity and inclusion: A modified e-Delphi study.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDemographic characteristics, social determinants of health (SDoH), health inequities, and health disparities substantially influence the general and disease-specific health outcomes of people with multiple sclerosis (MS). Participants in clinical trials do not represent all people with MS treated in practice.
objectiveTo provide recommendations for enhancing diversity and inclusion in clinical trials in MS.
methodsWe held an international workshop under the Auspices of the International Advisory Committee on Clinical Trials in MS (the "Committee") to develop recommendations regarding diversity and inclusivity of participants of clinical trials in MS. Workshop attendees included members of the Committee as well as external participants. External participants were selected based on expertise in trials, SDoH, health equity and regulatory science, and diversity with respect to gender, race, ethnicity, and geography.
resultsRecommendations include use of diversity plans, community engagement and education, cultural competency training, biologically justified rather than templated eligibility criteria, adaptive designs that allow broadening of eligibility criteria over the course of a trial, and logistical and practical adjustments to reduce study participant burden. Investigators should report demographic and SDoH characteristics of participants.
conclusionThese recommendations provide sponsors and investigators with methods of improving diversity and inclusivity of clinical trial populations in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.